Comparative evaluation of leucine-rich repeat kinase 2 and isthmin-1 immunoreactivity in malignant mesothelioma and reactive mesothelial hyperplasia

Ahmet Türk; Mustafa Yılmaz; Nevin Kocaman; Özlem Üçer; Gülsen Bayrak

Comparative evaluation of leucine-rich repeat kinase 2 and isthmin-1 immunoreactivity in malignant mesothelioma and reactive mesothelial hyperplasia

Abstract

Aims: This study was designed to investigate the immunohistochemical expression Leucine-Rich Repeat Kinase 2 (Dardarin, LRRK2) and Isthmin-1 (ISM-1) in tumor tissues from patients with MM, alongside a comparison to reactive mesothelial hyperplasia (RMH). Methods: A total of 60 MM and 60 RMH cases who had not received preoperative adjuvant therapy were included in the study. Immunohistochemical staining for LRRK2 and ISM-1 were conducted on 4-6 µm thick sections prepared from formalin-fixed, paraffin-embedded blocks. Results: Histopathological examination of MM cases revealed neoplastic formations with tubulopapillary architecture lined by mesothelial cells exhibiting moderate nuclear atypia and eosinophilic cytoplasm. In RMH cases, proliferating mesothelial cells lining an inflamed, edematous, and congested pleural surface were observed. Immunohistochemical analysis demonstrated that ISM-1 and LRRK2 expression levels were markedly elevated in MM tumor samples compared with RMH samples (p<0.001). Conclusion: Both LRRK2 and ISM-1 immunoreactivity were increased in malignant mesothelioma compared with RMH. However, the potential regulatory effects of these molecules on each other’s expression remain unclear. These results indicate that LRRK2 and ISM-1 could be clinically useful biomarkers for distinguishing MM from RMH and may also have potential prognostic value, highlighting the need for further research.

Keywords

References

Marinaccio A, Binazzi A, Marzio DD, et al. Pleural malignant mesothelioma epidemic: incidence, modalities of asbestos exposure and occupations involved from the Italian National Register. Int J Cancer. 2012;130(9):2146-2154. doi:10.1002/ijc.26229
Hajj GNM, Cavarson CH, Pinto CAL, Venturi G, Navarro JR, Lima VCC. Malignant pleural mesothelioma: an update. J Bras Pneumol. 2021;47(6):e20210129. doi:10.36416/1806-3756/e20210129
Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol. 2009;27(12):2081-2090. doi:10.1200/JCO. 2008.19.8523
Zucali PA, Ceresoli GL, De Vincenzo F, et al. Advances in the biology of malignant pleural mesothelioma. Cancer Treat Rev. 2011;37(7):543-558. doi:10.1016/j.ctrv.2011.01.001
Driscoll KE, Maurer JK, Higgins J, Poynter J. Alveolar macrophage cytokine and growth factor production in a rat model of crocidolite-induced pulmonary inflammation and fibrosis. J Toxicol Environ Health. 1995;46(2):155-169. doi:10.1080/15287399509532026
Leard LE, Broaddus VC. Mesothelial cell proliferation and apoptosis. Respirology. 2004;9(3):292-299. doi:10.1111/j.1440-1843.2004.00602
Mutsaers SE. Mesothelial cells: their structure, function and role in serosal repair. Respirology. 2002;7(3):171-191. doi:10.1046/j.1440-1843.2002.00404.x
Suzuki K, Kadota K, Sima CS, et al. Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. Cancer Immunol Immunother. 2011;60(12):1721-1728. doi:10.1007/s00262-011-1073-8

Ramos-Nino ME, Testa JR, Altomare DA, et al. Cellular and molecular parameters of mesothelioma. J Cell Biochem. 2006;98(4):723-734. doi:10. 1002/jcb.20828
Manning CB, Cummins AB, Jung MW, et al. A mutant epidermal growth factor receptor targeted to lung epithelium inhibits asbestos-induced proliferation and proto-oncogene expression. Cancer Res. 2002; 62(15):4169-4175.
Nicholson AG, Sauter JL, Nowak AK, et al. EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach. J Thorac Oncol. 2020;15(1):29-49. doi: 10.1016/j.jtho.2019.08.2506
Churg A, Naso JR. The separation of benign and malignant mesothelial proliferations: new markers and how to use them. Am J Surg Pathol. 2020;44(11):e100-e112. doi:10.1097/PAS.0000000000001565
Eguchi T, Kadota K, Mayor M, et al. Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1. Oncotarget. 2017;8(44): 77872-77882. doi:10.18632/oncotarget.20845
Husain AN, Chapel DB, Attanoos R, et al. Guidelines for pathologic diagnosis of mesothelioma: 2023 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2024;148(11):1251-1271. doi:10.5858/arpa.2023-0304-RA
Lee AF, Gown AM, Churg A. IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations. Am J Surg Pathol. 2013;37(3):421-426. doi:10.1097/PAS.0b013e31826ab1c0
Chang S, Oh MH, Ji SY, et al. Practical utility of insulin-like growth factor II mRNA-binding protein 3, glucose transporter 1, and epithelial membrane antigen for distinguishing malignant mesotheliomas from benign mesothelial proliferations. Pathol Int. 2014;64(12):607-612. doi: 10.1111/pin.12216
Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology. 2003;43(3):231-238. doi:10.1046/j.1365-2559.2003.01686.x
Hasteh F, Lin GY, Weidner N, Michael CW. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol. 2010;118(2):90-96. doi:10.1002/cncy. 20071
Jiang Z, Zhao M, Voilquin L, et al. Isthmin-1 is an adipokine that promotes glucose uptake and improves glucose tolerance and hepatic steatosis. Cell Metab. 2021;33(9):1836-1852.e11. doi:10.1016/j.cmet.2021.07.010
Hu M, Zhang X, Hu C, Teng T, Tang QZ. A brief overview about the adipokine: Isthmin-1. Front Cardiovasc Med. 2022;9:939757. doi:10.3389/fcvm.2022.939757
Zhou X, Zhang K, Wang C, et al. Isthmin-1 promotes growth and progression of colorectal cancer through the interaction with EGFR and YBX-1. Cancer Lett. 2024;590:216868. doi:10.1016/j.canlet.2024.216868
Turk A, Metin TO, Kuloglu T, et al. Isthmin-1 and spexin as promising novel biomarker candidates for invasive ductal breast carcinoma. Tissue Cell. 2024;91:102601. doi:10.1016/j.tice.2024.102601
Wu Y, Liang X, Ni J, et al. Effect of ISM1 on the immune microenvironment and epithelial-mesenchymal transition in colorectal cancer. Front Cell Dev Biol. 2021;9:681240. doi:10.3389/fcell.2021.681240
Rosenbusch KE, Oun A, Sanislav O, et al. A conserved role for LRRK2 and Roco proteins in the regulation of mitochondrial activity. Front Cell Dev Biol. 2021;9:734554. doi:10.3389/fcell.2021.734554
Yan J, Zhao W, Yu W, Cheng H, Zhu B. LRRK2 correlates with macrophage infiltration in pan-cancer. Genomics. 2022;114(1):316-327. doi:10.1016/j.ygeno.2021.11.037
Goveas L, Mutez E, Chartier-Harlin MC, Taymans JM. Mind the gap: LRRK2 phenotypes in the clinic vs. in patient cells. Cells. 2021;10(5):981. doi:10.3390/cells10050981
Jiang ZC, Chen XJ, Zhou Q, Gong XH, Chen X, Wu WJ. Downregulated LRRK2 gene expression inhibits proliferation and migration while promoting the apoptosis of thyroid cancer cells by inhibiting activation of the JNK signaling pathway. Int J Oncol. 2019;55(1):21-34. doi:10.3892/ijo.2019.4816
Jung K, Choi JS, Koo BM, et al. TM4SF4 and LRRK2 are potential therapeutic targets in lung and breast cancers through outlier analysis. Cancer Res Treat. 2021;53(1):9-24. doi:10.4143/crt.2020.434
Yang C, Pang J, Xu J, et al. LRRK2 is a candidate prognostic biomarker for clear cell renal cell carcinoma. Cancer Cell Int. 2021;21(1):343. doi:10. 1186/s12935-021-02047-y
Wallings R, Manzoni C, Bandopadhyay R. Cellular processes associated with LRRK2 function and dysfunction. FEBS J. 2015;282(15):2806-2826. doi:10.1111/febs.13305
Menghuan L, Yang Y, Qianhe M, et al. Advances in research of biological functions of isthmin-1. J Cell Commun Signal. 2023;17(3):507-521. doi:10. 1007/s12079-023-00732-3
Wang Y, Gao JZ, Sakaguchi T, et al. LRRK2 G2019S promotes colon cancer potentially via LRRK2-GSDMD axis-mediated gut inflammation. Cells. 2024;13(7):565. doi:10.3390/cells1307056
Lebovitz C, Wretham N, Osooly M, et al. Loss of Parkinson's susceptibility gene LRRK2 promotes carcinogen-induced lung tumorigenesis. Sci Rep. 2021;11(1):2097. doi:10.1038/s41598-021-81639-0

Details

Primary Language

English

Subjects

Pathology, Histology and Embryology

Journal Section

Research Article

Authors

Ahmet Türk ^*
0000-0003-0903-3522
Türkiye

Mustafa Yılmaz
0000-0002-4457-428X
Türkiye

Nevin Kocaman
0000-0002-6682-6345
Türkiye

Özlem Üçer
0000-0003-1877-7267
Türkiye

Gülsen Bayrak
0000-0002-1397-7203
Türkiye

Publication Date

May 22, 2026

Submission Date

February 17, 2026

Acceptance Date

April 10, 2026

Published in Issue

Year 2026 Volume: 8 Number: 3

IZ

https://izlik.org/JA56TJ62YF

Cite

RIS / Bibtex

APA

Türk, A., Yılmaz, M., Kocaman, N., Üçer, Ö., & Bayrak, G. (2026). Comparative evaluation of leucine-rich repeat kinase 2 and isthmin-1 immunoreactivity in malignant mesothelioma and reactive mesothelial hyperplasia. Anatolian Current Medical Journal, 8(3), 454-459. https://izlik.org/JA56TJ62YF

AMA

1.Türk A, Yılmaz M, Kocaman N, Üçer Ö, Bayrak G. Comparative evaluation of leucine-rich repeat kinase 2 and isthmin-1 immunoreactivity in malignant mesothelioma and reactive mesothelial hyperplasia. Anatolian Curr Med J / ACMJ / acmj. 2026;8(3):454-459. https://izlik.org/JA56TJ62YF

Chicago

Türk, Ahmet, Mustafa Yılmaz, Nevin Kocaman, Özlem Üçer, and Gülsen Bayrak. 2026. “Comparative Evaluation of Leucine-Rich Repeat Kinase 2 and Isthmin-1 Immunoreactivity in Malignant Mesothelioma and Reactive Mesothelial Hyperplasia”. Anatolian Current Medical Journal 8 (3): 454-59. https://izlik.org/JA56TJ62YF.

EndNote

Türk A, Yılmaz M, Kocaman N, Üçer Ö, Bayrak G (May 1, 2026) Comparative evaluation of leucine-rich repeat kinase 2 and isthmin-1 immunoreactivity in malignant mesothelioma and reactive mesothelial hyperplasia. Anatolian Current Medical Journal 8 3 454–459.

IEEE

[1]A. Türk, M. Yılmaz, N. Kocaman, Ö. Üçer, and G. Bayrak, “Comparative evaluation of leucine-rich repeat kinase 2 and isthmin-1 immunoreactivity in malignant mesothelioma and reactive mesothelial hyperplasia”, Anatolian Curr Med J / ACMJ / acmj, vol. 8, no. 3, pp. 454–459, May 2026, [Online]. Available: https://izlik.org/JA56TJ62YF

ISNAD

Türk, Ahmet - Yılmaz, Mustafa - Kocaman, Nevin - Üçer, Özlem - Bayrak, Gülsen. “Comparative Evaluation of Leucine-Rich Repeat Kinase 2 and Isthmin-1 Immunoreactivity in Malignant Mesothelioma and Reactive Mesothelial Hyperplasia”. Anatolian Current Medical Journal 8/3 (May 1, 2026): 454-459. https://izlik.org/JA56TJ62YF.

JAMA

1.Türk A, Yılmaz M, Kocaman N, Üçer Ö, Bayrak G. Comparative evaluation of leucine-rich repeat kinase 2 and isthmin-1 immunoreactivity in malignant mesothelioma and reactive mesothelial hyperplasia. Anatolian Curr Med J / ACMJ / acmj. 2026;8:454–459.

MLA

Türk, Ahmet, et al. “Comparative Evaluation of Leucine-Rich Repeat Kinase 2 and Isthmin-1 Immunoreactivity in Malignant Mesothelioma and Reactive Mesothelial Hyperplasia”. Anatolian Current Medical Journal, vol. 8, no. 3, May 2026, pp. 454-9, https://izlik.org/JA56TJ62YF.

Vancouver

1.Ahmet Türk, Mustafa Yılmaz, Nevin Kocaman, Özlem Üçer, Gülsen Bayrak. Comparative evaluation of leucine-rich repeat kinase 2 and isthmin-1 immunoreactivity in malignant mesothelioma and reactive mesothelial hyperplasia. Anatolian Curr Med J / ACMJ / acmj [Internet]. 2026 May 1;8(3):454-9. Available from: https://izlik.org/JA56TJ62YF